商品描述
This volume reviews key scientific principles and practices of passive antibody therapy for the treatment of infectious diseases. The main focus is on convalescent plasma, which is the most useful therapeutic option early in an epidemic, and may be especially important in low- and middle-income countries. The book's first section reviews the history of passive antibody therapies prior to the COVID pandemic, while the second section assesses convalescent plasma use during the COVID pandemic including evidence for safety and effectiveness, factors affecting efficacy, and the importance of convalescent plasma treatment of COVID-19 infections in the immunosuppressed. This section also addresses the roles played in the pandemic by monoclonal antibodies and hyperimmune globulins. Section three discusses the logistics of retrieving, storing and delivering convalescent plasma for therapy, and section four considers the role of passive antibody therapies in the event of a new pandemic involving an unknown microbial pathogen. In March 2020 the editors of this volume founded the national COVID-19 convalescent plasma project (ccpp19), an association of academic physicians organized to investigate the safety and effectiveness of convalescent plasma and to facilitate access to its use in the treatment of this new international pandemic.
Since that time, the project has produced more than 100 papers on almost every aspect of convalescent plasma usage in COVID-19 - treatment protocols, randomized trials, considerations of safety, conditions required for effectiveness, variability in use geographically and over time, application to vulnerable populations, regulatory issues, impact on overall COVID-19 mortality in the US and much else. At the same time, another form of antibody therapy - monoclonal antibodies - was being shown effective for out-patient use in COVID-19, confirming the principle of the value of antibody therapy in the early stages of disease, but lost effectiveness with viral mutation. A third form of antibody therapy - hyperimmune globulin, a preventive therapy with an excellent historical record of efficacy in several infectious diseases - holds great potential but was not effectively developed for COVID-19. This edited work brings together the central findings gained over the past years about passive antibody use and serves as an indispensable guide to best practices in the use of antibody therapies.
商品描述(中文翻譯)
本卷回顧了被動抗體療法在治療傳染病方面的關鍵科學原則和實踐。主要焦點是康復血漿，這是疫情初期最有用的治療選擇，對於低收入和中等收入國家尤其重要。本書的第一部分回顧了 COVID 疫情之前被動抗體療法的歷史，而第二部分則評估了在 COVID 疫情期間康復血漿的使用，包括安全性和有效性的證據、影響療效的因素，以及康復血漿在免疫抑制者 COVID-19 感染治療中的重要性。這一部分還討論了單克隆抗體和高免疫球蛋白在疫情中的角色。第三部分討論了檢索、儲存和交付康復血漿以進行治療的物流，第四部分則考慮了在涉及未知微生物病原體的新疫情中，被動抗體療法的角色。
在 2020 年 3 月，本卷的編輯創立了全國 COVID-19 康復血漿計畫 (ccpp19)，這是一個由學術醫生組成的協會，旨在調查康復血漿的安全性和有效性，並促進其在治療這一新國際疫情中的使用。
自那時以來，該計畫已經產出了超過 100 篇有關 COVID-19 中康復血漿使用的幾乎所有方面的論文——治療方案、隨機試驗、安全性考量、有效性所需條件、地理和時間上的使用變異性、對脆弱人群的應用、監管問題、對美國整體 COVID-19 死亡率的影響等等。與此同時，另一種抗體療法——單克隆抗體——在 COVID-19 的門診使用中顯示出有效性，確認了抗體療法在疾病早期階段的價值原則，但隨著病毒突變而失去有效性。第三種抗體療法——高免疫球蛋白，這是一種在幾種傳染病中具有優秀歷史療效的預防療法——具有很大的潛力，但在 COVID-19 中未能有效開發。本編輯作品匯集了過去幾年有關被動抗體使用的核心發現，並作為使用抗體療法最佳實踐的不可或缺的指南。
作者簡介
Nigel Paneth MD MPH is University Distinguished Professor Emeritus in the Departments of Epidemiology & Biostatistics and Pediatrics & Human Development in the College of Human Medicine at Michigan State University. He received his MD degree from Harvard University and trained in Pediatrics at the Albert Einstein College of Medicine/Jacobi Hospital in New York City. He obtained the MPH degree in Epidemiology from the Columbia University School of Public Health following his residency. After faculty appointments at Einstein and Columbia, he moved to Michigan State University to establish a Department of Epidemiology in the College of Human Medicine. The unit began as a program in 1989, achieved departmental status in 1998, with Paneth as its first chair, and was renamed Epidemiology and Biostatistics in 2013. His central research focus has been on the origins and consequences of brain damage originating in pregnancy and the perinatal period with a special focus on the problems of premature infants. He has authored more than 400 articles in the scientific press, many derived from three large NIH-funded long-term observational cohort studies of premature infants which he directed or co-directed - The Neonatal Brain Hemorrhage Study (1984-2004) the Developmental Epidemiology Network Study (1991-96) and Extremely Low Gestational Age Newborn Study (2001 - present). Two scientific monographs emerged from these studies, with Paneth as co-author or editor - Brain Damage in the Preterm Infant (MacKeith Press, 1994) and Extremely Preterm Birth and its Consequences) MacKeith Press, 2014). He also co-edited the textbook: Cerebral Palsy: Science and Practice (McKeith Press, 2014). His interest in medical history, reflected in chapter 2 of this volume, is indicated by his co-authorship of Cholera, Chloroform and the Science of Medicine: A Life of John Snow (Oxford University Press, 2003). He has received the Kathleen Lyle Murray award of the American Academy of Cerebral Palsy (with John L. Kiely), the Weinstein-Goldenson Medical Science Award of the United Cerebral Palsy Research and Education Foundation and the Advancing Knowledge Award of the Coalition for Excellence in Maternal and Child Health Epidemiology. During the COVID-19 pandemic Dr. Paneth was a member of the leadership team of the National Convalescent Plasma Project, which assisted in the deployment of convalescent plasma and which saved tens of thousands of lives in the United States. Michael J Joyner MD is the Caywood Professor of Anesthesiology and Perioperative Medicine at the Mayo Clinic and Mayo Clinic College of Medicine in Rochester, Minnesota. He received his MD degree (1987) from the University of Arizona and trained in Anesthesiology at the Mayo Graduate School of Medicine. He participated in specialized research training in both programs. After residency, in 1993 he was appointed to the staff of the Mayo clinic where he established the Human Integrative Physiology and Pharmacology laboratory in the Department of Anesthesiology and Perioperative Medicine. Over the years Joyner has been the Vice Dean for Research at Mayo, Vice Chair of the Department Anesthesiology and Perioperative Medicine, and a co-Principal Investigator for the institutions NIH funded GCRC and CTSA programs. Joyner's central research focus has been on integrative physiological responses in humans to stressors like exercise, hypoxia, hyperthermia, and mental stress with a special emphasis on how sex differences and aging impact these responses. He has authored more than 600 articles in the scientific press and been funded by the NIH since the early 1990s. In addition to these interests and achievements, Joyner is considered one of the world's leading experts on human athletic performance. He has numerous publications on related topics including developing the physiological "Joyner model" of human endurance performance in the early 1990s. He has received lifetime achievement awards from the American Physiological Society and the American College of Sports Medicine and an honorary doctorate from McMaster University (Canada). More than 30 of his former fellows have established independent laboratories at leading research institutions in the North America, Japan and Europe. During the COVID-19 pandemic Dr. Joyner repurposed his physiologically oriented research program to focus on convalescent plasma and COVID-19. He was a member of the leadership team of the National Convalescent Plasma Project, which assisted in the deployment of convalescent plasma, and which saved tens of thousands of lives in the United States. Additionally, he was the principal investigator of the US Expanded Access Program for convalescent plasma. As the pandemic waned, he shifted his focus to the use of convalescent plasma in immunocompromised patients unable to generate endogenous antibodies. A highly effective use case the was fully licensed and approved by the US Food and Drug Administration in late 2024. Arturo Casadevall, M.D., Ph.D., is a Bloomberg Distinguished Professor and Chair of the Department of Molecular Microbiology and Immunology at Johns Hopkins School of Public Health. He received his M.D. and Ph.D. degrees from New York University and completed his internship/residency in internal medicine at Bellevue Hospital. The author of over a thousand papers, his major research interests are in fungal pathogenesis and the mechanisms of antibody action. He is editor-in-chief of mBio, Deputy Editor of the Journal of Clinical Investigation and serves on several numerous editorial boards. He has served on several NIH committees including the NIAID Strategic Plan, the Blue-Ribbon Panel on Biodefense Research, the NAS panel that reviewed the FBI investigation on anthrax attacks, the NAS Federal Regulations and Reporting committee and the National Science Advisory Board for Biosecurity. He was a Commissioner in the National Commission on Forensic Science and previously served as President of the Medical Mycology Society of the Americas. He served as the Chair the Board of Governors of the American Academy of Microbiology. He has received numerous honors including election to the American Society for Clinical Investigation, American Academy of Physicians, American Academy of Microbiology, Fellow of the American Academy for the Advancement of Science, American Academy of Arts and Sciences, the National Academy of Medicine, the National Academy of Sciences, Distinguished Fellow in Immunology and the Council for Foreign Relations. Dr. Casadevall is also interested in the problems with scientific enterprise and, with collaborators, he showed that misconduct accounts for the majority of retracted publications. He has studied processes in science with the goal of making it more equitable and has shown that inequities in gender balance at meetings and in authorship can be remedied by changing practices. Two books authored by Dr. Casadevall deal with scientific issues and were written for the public. In 'What if Fungi win?' (Johns Hopkins Press, 2024), he introduces readers to the fungal world discussing all its benefits and threats. In 'Thinking about Science: Good Science, Bad Science and How to Make it Better' (Wiley, 2023), written with Dr. Ferric Fang, the authors address the marvel that is current science while also discussing the problems of the discipline. During the COVID-19 pandemic Dr. Casadevall was a member of the leadership team of the National Convalescent Plasma Project, which assisted in the deployment of convalescent plasma and which saved tens of thousands of lives in the United States.
作者簡介(中文翻譯)
奈傑爾·潘尼斯醫學博士公共衛生碩士是密西根州立大學人類醫學學院流行病學與生物統計學及兒科與人類發展系的榮譽大學傑出教授。他在哈佛大學獲得醫學博士學位，並在紐約市的阿爾伯特·愛因斯坦醫學院/雅各比醫院接受兒科訓練。隨後，他在哥倫比亞大學公共衛生學院獲得流行病學的公共衛生碩士學位。 在愛因斯坦醫學院和哥倫比亞大學任教後，他轉到密西根州立大學，成立了人類醫學學院的流行病學系。該單位於1989年開始作為一個計劃，於1998年獲得系級地位，潘尼斯擔任首任系主任，並於2013年更名為流行病學與生物統計學。 他的主要研究重點是孕期及圍產期腦損傷的起源及後果，特別關注早產兒的問題。他在科學期刊上發表了400多篇文章，其中許多來自他主導或共同主導的三項大型國立衛生研究院（NIH）資助的長期觀察性隊列研究——新生兒腦出血研究（1984-2004）、發展流行病學網絡研究（1991-96）和極低胎齡新生兒研究（2001年至今）。這些研究產生了兩本科學專著，潘尼斯是共同作者或編輯——《早產兒的腦損傷》（MacKeith Press, 1994）和《極早產及其後果》（MacKeith Press, 2014）。他還共同編輯了教科書：《腦性麻痺：科學與實踐》（McKeith Press, 2014）。他對醫學歷史的興趣在本卷的第二章中有所體現，他是《霍亂、氯仿與醫學科學：約翰·斯諾的生活》（牛津大學出版社，2003）的共同作者。 他獲得了美國腦性麻痺學會的凱瑟琳·萊爾·穆雷獎（與約翰·L·基利共同獲得）、美國腦性麻痺研究與教育基金會的韋恩斯坦-戈登醫學科學獎以及母嬰健康流行病學卓越聯盟的知識推進獎。 在COVID-19大流行期間，潘尼斯博士是全國康復血漿計劃的領導團隊成員，該計劃協助部署康復血漿，拯救了美國數萬條生命。 邁克爾·J·喬伊納醫學博士是明尼蘇達州羅徹斯特的梅奧診所及梅奧醫學院的麻醉學與圍手術醫學的凱伍德教授。他於1987年在亞利桑那大學獲得醫學博士學位，並在梅奧研究生醫學院接受麻醉學訓練。他參加了兩個項目的專門研究訓練。 在完成住院醫師訓練後，1993年他被任命為梅奧診所的職員，並在麻醉學與圍手術醫學系建立了人類整合生理學與藥理學實驗室。多年來，喬伊納擔任梅奧的研究副院長、麻醉學與圍手術醫學系的副主任，以及該機構NIH資助的GCRC和CTSA計劃的共同首席研究員。 喬伊納的主要研究重點是人類對運動、缺氧、高溫和心理壓力等壓力源的整合生理反應，特別強調性別差異和老化如何影響這些反應。他在科學期刊上發表了600多篇文章，自1990年代初以來獲得了NIH的資助。除了這些興趣和成就外，喬伊納被認為是全球人類運動表現的領先專家之一。他在相關主題上有許多出版物，包括在1990年代初期開發的生理學“喬伊納模型”以解釋人類耐力表現。 他獲得了美國生理學會和美國運動醫學學會的終身成就獎，以及加拿大麥克馬斯特大學的榮譽博士學位。他的30多位前研究員在北美、日本和歐洲的頂尖研究機構建立了獨立的實驗室。 在COVID-19大流行期間，喬伊納博士將其以生理學為導向的研究計劃重新調整為專注於康復血漿和COVID-19。他是全國康復血漿計劃的領導團隊成員，該計劃協助部署康復血漿，拯救了美國數萬條生命。此外，他還是美國康復血漿擴大使用計劃的首席研究員。隨著大流行的減退，他將重點轉向使用康復血漿治療無法產生內源性抗體的免疫抑制患者。這是一個在2024年底獲得美國食品藥品監督管理局完全授權和批准的高效用例。 阿圖羅·卡薩德瓦爾醫學博士，哲學博士，是約翰霍普金斯公共衛生學院分子微生物學與免疫學系的布隆伯格傑出教授及系主任。他在紐約大學獲得醫學博士和哲學博士學位，並在貝爾維尤醫院完成內科實習/住院醫師訓練。作為一位發表超過一千篇論文的作者，他的主要研究興趣在於真菌致病性和抗體作用機制。 他是mBio的主編、《臨床研究雜誌》的副編輯，並在多個編輯委員會任職。他曾在多個NIH委員會任職，包括NIAID戰略計劃、生物防禦研究藍絲帶小組、審查FBI對炭疽攻擊調查的NAS小組、NAS聯邦法規與報告委員會以及國家科學安全諮詢委員會。他曾是全國法醫科學委員會的專員，並曾擔任美國醫學真菌學會的會長。他還擔任美國微生物學學會的理事會主席。他獲得了多項榮譽，包括當選美國臨床研究學會、美國醫學學院、美國微生物學學會、美國科學促進會、藝術與科學學院、國家醫學學院、國家科學院的榮譽會員，以及免疫學的傑出會員和外交關係委員會的成員。 卡薩德瓦爾博士還對科學企業中的問題感興趣，並與合作者一起顯示不當行為佔據了大多數撤回的出版物。他研究科學過程，旨在使其更加公平，並顯示會議和作者身份中的性別平衡不平等可以通過改變做法來改善。 卡薩德瓦爾博士撰寫的兩本書涉及科學問題，並為公眾所寫。在《如果真菌獲勝會怎樣？》（約翰霍普金斯出版社，2024）中，他向讀者介紹了真菌世界，討論了其所有的好處和威脅。在《思考科學：好科學、壞科學及如何改善》（Wiley，2023）中，與費瑞克·方博士共同撰寫，作者們探討了當前科學的奇蹟，同時也討論了該學科的問題。 在COVID-19大流行期間，卡薩德瓦爾博士是全國康復血漿計劃的領導團隊成員，該計劃協助部署康復血漿，拯救了美國數萬條生命。
